words by mary ann littell / photograph by pete byron
oretta Mueller, DO, has been principal or co-investigator for more than 50 clinical trials since beginning her career in the early 1990s. She has studied most of the migraine medications that have been approved during this exciting time for headache research.
Mueller has just finished enrolling patients for a totally new drug class for alleviation of migraine headaches, called a calcitonin-gene related peptide antagonist, which is not believed to cause blood vessel constriction (an issue with using migraine-specific medicines in patients with risk factors or known heart disease). She is also author and principal investigator of a funded, investigator-initiated study examining headache recurrences that occur more than a day after initial relief with medication, and looking at quality of life and satisfaction scales in reference to recurrence.